Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | FLT4 | P35916 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180024 | 0.85 | KDM4E (0.60) | TYK2KDM4ECYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7091405 | 0.85 | RAB9A (0.65) | TYK2JAK2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL516293 | 0.84 | ABL1 (0.46) | TYK2JAK2KDM4ECYP1A2CYP2D6 | |
| SCHEMBL1014886 | 0.84 | ALDH1A1 (0.53) | TYK2JAK2KDM4ECYP1A2CYP2D6 | |
| SCHEMBL3142619 | 0.83 | TYK2 (0.55) | TYK2JAK2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL295414 | 0.83 | SMN1; SMN2 (0.57) | TYK2JAK2KDM4EFLT1FLT4 | |
| SCHEMBL473972 | 0.83 | ALDH1A1 (0.65) | TYK2JAK2KDM4ECYP1A2CYP2C19 | |
| SCHEMBL21434767 | 0.83 | PDK2 (0.47) | TYK2JAK2KDM4ECYP2C9RAB9A | |
| SCHEMBL21447016 | 0.83 | TDP1 (0.51) | KDM4ERAB9AMAPTABL1NPC1 | |
| SCHEMBL28794849 | 0.83 | ABL1 (0.45) | TYK2JAK2KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2018068295-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | Piramal Enterprises Limited (IN) | 2013-02-21 | — | — | US | disclosed |
| US-8304449-B2 | Inhibitors of cyclin dependent kinases and their use | PIRAMAL HEALTHCARE LIMITED (IN) | 2012-11-06 | — | — | US | disclosed |
| CN-1668613-B | Flavone derivatives as cyclin dependent kinase inhibitors | NICHOLAS PIRAMAL INDIA LTD | 2012-07-04 | — | — | CN | disclosed |
| WO-2012052395-A1 | ISOXAZOLE DERIVATIVES USED AS OESTROGEN MODULATORS | N. V. ORGANON (NL) | 2012-04-26 | — | — | WO | disclosed |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | PIRAMAL LIFE SCIENCES LTD. (IN) | 2011-06-09 | — | — | US | disclosed |
| US-7915301-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one | Piramal Life Science Limited (IN) | 2011-03-29 | — | — | US | disclosed |
| US-7884127-B2 | chromenone derivatives of nitrogen-, oxygen- or sulfur-containing saturated heterocycles; preparation by cyclizing benzoyl intermediates; antiproliferative agents; 2-(2-Chloro-phenyl)-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-5,7-dimethoxy-chromen-4-one; acidification | Pirimal Life Sciences Ltd. (IN) | 2011-02-08 | — | — | US | disclosed |
| US-7045539-B2 | Therapeutic benzoxazole compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| CN-1668613-A | Flavone derivatives as cyclin dependent kinase inhibitors | NICHOLAS PIRAMAL INDIA LTD (IN) | 2005-09-14 | — | — | CN | disclosed |
| EP-1556375-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | Nicholas Piramal India Limited (IN) | 2005-07-27 | — | — | EP | disclosed |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-06-03 | — | — | US | disclosed |
| US-20040102435-A1 | Therapeutic compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| WO-2004004632-A2 | FLAVONE DERIVATIVES AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2004-01-15 | — | — | WO | disclosed |
| EP-1345914-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002051821-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-07-04 | — | — | WO | disclosed |
| US-5856574-A | ANTIISCHEMIC AGENTS; ANTIARRTHYMIA AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247754-A1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | TYK2 1465/4885JAK2 1724/4885KDM4E 1375/4885 |
| US-20040102435-A1 | Therapeutic compounds | ESRRA, ESRRG, ESR2 | TYK2 1494/4885JAK2 969/4885KDM4E 2759/4885 |
| US-20040106581-A1 | Inhibitors of cyclin-dependent kinases and their use | CCNK, CCNI, CDK1 | TYK2 554/4885JAK2 379/4885KDM4E 1718/4885 |
| US-20110136873-A1 | Inhibitors of Cyclin Dependent Kinases and Their Use | CDK1, CCNK, CCNI | TYK2 438/4885JAK2 300/4885KDM4E 1821/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | TYK2 1465/4885JAK2 1724/4885KDM4E 1375/4885 |
| US-20130045993-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES AND THEIR USE | CDK1, CCNK, CCNI | TYK2 528/4885JAK2 265/4885KDM4E 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.